Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

GlaxoSmithKline379 enrolled

Overview

The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of valaciclovir in pediatric patients with chickenpox

Study Type

OBSERVATIONAL

Enrollment

379

Conditions

Varicella

Interventions

ValaciclovirDRUG

Eligibility

Sex: ALLMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pediatric patients with chickenpox (aged less than 15 years old). Exclusion Criteria: * Patients with a history of hypersensitivity to the ingredients of valaciclovir or acyclovir.

Outcomes

Primary Outcomes

Number of Participants With Any Serious Adverse Event

A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or results in prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. For a list of all serious adverse events occurring during the course of the study, please see the table entitled "Serious Adverse Events" in the Adverse Event section of the results record.

Time frame: 1 month

Secondary Outcomes

Number of Participants With the Indicated Adverse Drug Reactions

An adverse drug reaction (ADR) is an adverse event whose causal relationship to study drug was not ruled out by the reporting physician. An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. For a list of all ADRs occurring during the course of the study, please also see the table entitled "Other (non-serious) adverse events" in the Adverse Event section of the results record.

Time frame: 1 month

Number of Participants With Any Unexpected Adverse Drug Reactions

An unexpected adverse drug reaction is an adverse event whose casual relationship to the study drug is not ruled out by the reporting physician and also is not listed in a package insert of the drug.

Time frame: 1 month

Number of Participants Classified as Effective and Not Effective

The course of symptoms was comprehensively assessed by the investigator on a four-category scale (Improved, Unchanged, Worsen, and Unassessable) before and after the initiation of valaciclovir therapy. "Improved" was regarded as "Effective," and "Unchanged" and " Worsen" were regarded as "Not effective." The two participants classifed as "Not effective" were classified as "Unchanged."

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.